No recycled or generic COAs
HC Lavapis: M Carmen lvarez Orviz, Jess Herrero Hernndez, M Veredas Gonzlez Mrquez, M Jess Lpez Rodrguez, M de las Maravillas Almarza Garca, M Teresa San Clemente Pastor, M mparo Corral Rubio
Subcutaneous injection protocol: Starting dose: 200 to 300 mcg daily Titration: Increase by approximately 100 mcg every 1 to 2 weeks as tolerated Target dose: 400 to 500 mcg daily by weeks 5 through 12 Frequency: Once daily, subcutaneous Cycle length: 8 to 12 weeks, with optional extension to 16 weeks Timing: Consistent daily timing, typically evening for sleep applications Oral/sublingual protocol: Duration: 30 days Frequency: 1 to 4 cycles per year Best combined with: Exercise and nutrient-rich diet Injection sites should be rotated between the abdomen, thighs, and upper arms to prevent lipohypertrophy and ensure consistent absorption
Two format notes
Combining Injectable with Topical Application Maximum results often come from combining injectable GHK-Cu with topical scalp application
Expression of kisspeptins and kisspeptin receptor in the kidney of chronic renal failure rats